+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Nasal Polyps Treatment Market, by Drug Class, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

  • PDF Icon

    Report

  • 520 Pages
  • August 2022
  • Region: Global
  • Coherent Market Insights Pvt Ltd.
  • ID: 5669067
Nasal polyps develop in swollen tissue of the nasal mucosa. The mucosa is a very wet layer that protects the inside of nose and sinuses. During a contamination or allergy-induced irritation, the nasal mucosa becomes swollen and red, and it produces liquid that drips out. With prolonged irritation, the mucosa can form a polyp. A nasal polyp is a round growth that can block nasal passages.

Nasal polyps grow large enough that may to block nasal passages, which causes chronic congestion. Its system includes a sensation like block nose, runny nose, a feeling of pressure in forehead or face nasal stuffiness, nasal congestion, reduced sense of smell etc. Medications that decrease swelling may help reduce the size of the polyp and dismiss symptoms of congestion. Spraying nasal steroids into the nose can decrease runny nose and the sensation of block by reduction the nasal polyp. If nasal polyps are not cured with drugs, surgery can eliminate the nasal polyps totally.

Market Dynamics

Market players are getting approvals from regulatory bodies to develop new therapy for the treatment of nasal polys, which is expected to drive growth of the global nasal polyps treatment market, over the forecast period. For instance, according to data published in SAGE Journals, a publishing company, as on October 9, 2020, the U.S. Food and Drug Administration had approved biologic therapy as a new treatment for the patients suffering with chronic rhinosinusitis with nasal polyps. Biologics aim and reduce type 2 cytokine inflammation, and is one of the novel treatment opportunities for patients with chronic rhinosinusitis with nasal polyps.

Increasing prevalence of sinuses related diseases is expected to drive growth of the global nasal polyps treatment market, over the forecast period. For instance, according to report of 2018 by Centers for Disease Control and Prevention, in the U.S. about 28.9 million people above age 18 were diagnosed with sinusitis. Sinusitis is an inflammation of the tissue lining the sinuses. Increase in number of sinusitis disease among the population would result in high demand for the treatment, which would drive growth of the nasal polyps treatment market

Key features of the study:

  • This report provides an in-depth analysis of the global nasal polyps treatment market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global nasal polyps treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Regeneron Pharmaceuticals, Inc., Hoffmann-La Roche Ag, Fougera Pharmaceuticals Inc., Novartis International Ag, Sanofi S.A., GlaxoSmithKline Plc, Intersect Ent, Dohme Corp, Merck & Co., Inc., Sanofi S.A., Norton Waterford Ltd, Astrazeneca Plc, Taro Pharmaceuticals Industries Ltd., Teva Pharmaceutical Industries Limited, and OptiNose Inc.
  • Insights from this report would allow marketers and management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global nasal polyps treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nasal polyps treatment market.

Detailed Segmentation:

Global Nasal Polyps Treatment Market, By Drug Class:

  • Corticosteroids
  • Nasal corticosteroids
  • Fluticasone
  • Budesonide
  • Mometasone
  • Triamcinolone
  • Others - Beclomethasone, Ciclesonide, etc.
  • Oral/Injectable Corticosteroids
  • Prednisone
  • Combination
  • Antibiotics
  • Antihistamines
  • Interleukin Inhibitors
  • Dupilumab
  • Others (IL 10, IL 25 etc.)
  • Monoclonal Antibodies
  • Mepolizumab
  • Omalizumab
  • Others
  • Others (Aspirin, anticholinergic agent and etc.)

Global Nasal Polyps Treatment Market, By Route of Administration:

  • Nasal
  • Oral
  • Parenteral

Global Nasal Polyps Treatment Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Nasal Polyps Treatment Market, By Region:

  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • Central Africa
  • North Africa
  • Company Profiles
  • Regeneron Pharmaceuticals, Inc *
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Hoffmann-La Roche Ag
  • Fougera Pharmaceuticals Inc.,
  • Novartis International Ag
  • Sanofi S.A.
  • GlaxoSmithKline Plc
  • Intersect Ent
  • Dohme Corp
  • Merck & Co., Inc.
  • Norton Waterford Ltd
  • Astrazeneca Plc
  • Taro Pharmaceuticals Industries Ltd.
  • Teva Pharmaceutical Industries Limited
  • OptiNose Inc.
* marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions
  • Research Objectives
  • Assumptions
  • Abbreviations
2. Market Overview
  • Report Description
  • Market Definition and Scope
  • Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Route of Administration
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
3. Market Dynamics, Regulations, and Trends Analysis
  • Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
  • Impact Analysis
  • Regulatory Scenario
  • PEST Analysis
  • Recent Product Launch/Approval
  • Epidemiology
  • Mergers and Acquisitions
4. Global Nasal Polyps Treatment Market- Impact of Coronavirus (Covid-19) Pandemic
  • Impact on Supply Chain
  • Impact on Research and Development
  • Government Initiatives
5. Global Nasal Polyps Treatment Market, By Drug Class, 2017-2030 (US$ Million)
  • Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
  • Corticosteroids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Nasal corticosteroids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Fluticasone
  • Budesonide
  • Mometasone
  • Triamcinolone
  • Others - Beclomethasone, Ciclesonide, etc.
  • Oral/Injectable Corticosteroids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Prednisone
  • Combination
  • Antibiotics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Antihistamines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Interleukin Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Dupilumab
  • Others (IL 10, IL 25 etc.)
  • Monoclonal Antibodies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Mepolizumab
  • Omalizumab
  • Others
  • Others (Aspirin, anticholinergic agent and etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
6. Global Nasal Polyps Treatment Market, By Route of Administration, 2017 - 2030 (US$ Million)
  • Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
  • Nasal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Parenteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
7. Global Nasal Polyps Treatment Market, By Distribution Channel, 2017 - 2030 (US$ Million)
  • Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
  • Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
8. Global Nasal Polyps Treatment Market, By Region, 2017 - 2030 (US$ Million)
  • Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017 - 2030
  • Regional Trends
  • North America
  • Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
  • U.S.
  • Canada
  • Latin America
  • Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
  • South Africa
  • Central Africa
  • North Africa
9. Competitive Landscape
  • Company Profiles
  • Regeneron Pharmaceuticals, Inc.
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Hoffmann-La Roche Ag
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Fougera Pharmaceuticals Inc.,
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Novartis International Ag
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Sanofi S.A.
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • GlaxoSmithKline Plc
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Intersect Ent
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Dohme Corp
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Merck & Co., Inc.
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Norton Waterford Ltd
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Astrazeneca Plc
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Taro Pharmaceuticals Industries Ltd.
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Teva Pharmaceutical Industries Limited
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • OptiNose Inc.
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Analyst Views
10. Section
  • References
  • Research Methodology
  • About us and Sales Contact

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Regeneron Pharmaceuticals, Inc
  • Hoffmann-La Roche Ag
  • Fougera Pharmaceuticals Inc.,
  • Novartis International Ag
  • Sanofi S.A.
  • GlaxoSmithKline Plc
  • Intersect Ent
  • Dohme Corp
  • Merck & Co., Inc.
  • Norton Waterford Ltd
  • Astrazeneca Plc
  • Taro Pharmaceuticals Industries Ltd.
  • Teva Pharmaceutical Industries Limited
  • OptiNose Inc.